Intendis management introduced the new company and its growth prospects at a press conference in Berlin, Germany. The company plans to invest in the marketing of the group’s well-established dermatology brands in the areas of eczema, psoriasis, acne, rosacea, and fungal infections to broaden their global reach.
In addition, Intendis is developing new medical entities to further expand the business in areas with the greatest unmet medical need and promising growth.
“We are looking forward to growing Intendis into a major specialist dermatology company and to become a partner of choice in our field,” said Professor Wolfgang Kehr, CEO of Intendis GmbH. “We expect that our strong brands and dedication to new product development will ensure sales growth above current market growth. We clearly aim to maximize the growth potential of our business.”
Intendis showed pro forma net sales of E200 million for 2004 and has the rights to leading dermatology brands transferred from Schering AG, including Advantan, Finacea and Psorcutan. It is headquartered in Berlin and has over 600 employees worldwide in manufacturing, development, marketing and sales across ten key dermatology markets.